High proteolytic resistance of spider-derived inhibitor cystine knots

International Journal of Peptides

Volumn 2015, Issue , 2015, Pages

  Kikuchi, Kyoko ^a   Sugiura, Mika ^a   Kimura, Tadashi ^a,b  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN TRYPSIN; CYSTINE; ELASTASE; ION CHANNEL; PEPSIN A; PEPTIDE; PROTEIN INHIBITOR; PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CIRCULATION; CLEARANCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABSORPTION; DRUG MECHANISM; ENZYME BLOOD LEVEL; GASTROINTESTINAL TRACT; HUMAN; IN VITRO STUDY; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SPIDER; STOMACH;

EID: 84956942138     PISSN: 16879767     EISSN: 16879775     Source Type: Journal    
DOI: 10.1155/2015/537508     Document Type: Article

References (48)

1. A. Bernkop-Schnurch, "The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins, " Journal of Controlled Release, vol. 52, no. 1-2, pp. 1-16, 1998.
2. B. F. Choonara, Y. E. Choonara, P. Kumar, D. Bijukumar, L. C. du Toit, and V. Pillay, "A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules, " Biotechnology Advances, vol. 32, no. 7, pp. 1269-1282, 2014.
3. V. K. Pawar, J. G. Meher, Y. Singh, M. Chaurasia, B. S. Reddy, and M. K. Chourasia, "Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives, " Journal of Controlled Release, vol. 196, pp. 168-183, 2014.
4. M. Werle and A. Bernkop-Schnurch, "Strategies to improve plasma half life time of peptide and protein drugs, "Amino Acids, vol. 30, no. 4, pp. 351-367, 2006.
5. K. Fosgerau and T. Hoffmann, "Peptide therapeutics: current status and future directions, " Drug Discovery Today, vol. 20, no. 1, pp. 122-128, 2015.
6. C. I. Schroeder and D. J. Craik, "Therapeutic potential of conopeptides, " Future Medicinal Chemistry, vol. 4, no. 10, pp. 1243-1255, 2012.
7. V. Truong-Le, P. M. Lovalenti, and A. M. Abdul-Fattah, "Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems, " Advanced Drug Delivery Reviews, vol. 93, pp. 95-108, 2015.
8. G. F. King, "Venoms as a platform for human drugs: translating toxins into therapeutics, " Expert Opinion on BiologicalTherapy, vol. 11, no. 11, pp. 1469-1484, 2011.
9. R. J. Clark, H. Fischer, L. Dempster et al., "Engineering stable peptide toxins by means of backbone cyclization: stabilization of the α-conotoxin MII, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 13767-13772, 2005.
10. C. J. Armishaw, N. L. Daly, S. T. Nevin, D. J. Adams, D. J. Craik, and P. F. Alewood, "α-selenoconotoxins, a new class of potent α7 neuronal nicotinic receptor antagonists, " The Journal of Biological Chemistry, vol. 281, no. 20, pp. 14136-14143, 2006.
11. M. L. Colgrave and D. J. Craik, "Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot, " Biochemistry, vol. 43, no. 20, pp. 5965-5975, 2004.
12. D. J. Craik, N. L. Daly, and C. Waine, "The cystine knot motif in toxins and implications for drug design, " Toxicon, vol. 39, no. 1, pp. 43-60, 2001.
13. A. Heitz, O. Avrutina, D. Le-Nguyen et al., "Knottin cyclization: impact on structure and dynamics, " BMC Structural Biology, vol. 8, article 54, 2008.
14. H. Kolmar, "Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins, " Current Opinion in Pharmacology, vol. 9, no. 5, pp. 608-614, 2009.
15. M. Reinwarth, D. Nasu, H. Kolmar, and O. Avrutina, "Chemical synthesis, backbone cyclization and oxidative folding of cystineknot peptides-promising scaffolds for applications in drug design, " Molecules, vol. 17, no. 11, pp. 12533-12552, 2012.
16. C. P. Sommerhoff, O. Avrutina, H.-U. Schmoldt, D. Gabrijelcic- Geiger, U. Diederichsen, and H. Kolmar, "Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase β, " Journal ofMolecular Biology, vol. 395, no. 1, pp. 167-175, 2010.
17. H. G. Park, S. S. Kyung, K. S. Lee et al., "Dual function of a bee (Apis cerana) inhibitor cysteine knot peptide that acts as an antifungal peptide and insecticidal venom toxin, " Developmental and Comparative Immunology, vol. 47, no. 2, pp. 247-253, 2014.
18. B. Gao, C. Tian, and S. Zhu, "Inducible antibacterial response of scorpion venom gland, " Peptides, vol. 28, no. 12, pp. 2299-2305, 2007.
19. C. Pimentel, S.-J. Choi, B. Chagot, C. Guette, J.-M. Camadro, and H. Darbon, "Solution structure of PcFK1, a spider peptide active against Plasmodium falciparum, " Protein Science, vol. 15, no. 3, pp. 628-634, 2006.
20. T. Kimura, S. Ono, and T. Kubo, "Molecular cloning and sequence analysis of the cDNAS encoding toxin-like peptides from the venom glands of tarantula Grammostola rosea, " International Journal of Peptides, vol. 2012, Article ID 731293, 10 pages, 2012.
21. S. Ono, T. Kimura, and T. Kubo, "Characterization of voltagedependent calcium channel blocking peptides from the venom of the tarantula Grammostola rosea, " Toxicon, vol. 58, no. 3, pp. 265-276, 2011.
22. J. J. Smith, V. Herzig, G. F. King, and P. F. Alewood, "The insecticidal potential of venompeptides, " Cellular andMolecular Life Sciences, vol. 70, no. 19, pp. 3665-3693, 2013.
23. B. Dworakowska and K. Dolowy, "Ion channels-related diseases, " Acta Biochimica Polonica, vol. 47, no. 3, pp. 685-703, 2000.
24. D. Conte Camerino, D. Tricarico, and J.-F. Desaphy, "Ion channel pharmacology, " Neurotherapeutics, vol. 4, no. 2, pp. 184-198, 2007.
25. S. C. Cannon, "Physiologic principles underlying ion channelopathies, " Neurotherapeutics, vol. 4, no. 2, pp. 174-183, 2007.
26. A. Mathie, "Ion channels as novel therapeutic targets in the treatment of pain, " Journal of Pharmacy and Pharmacology, vol. 62, no. 9, pp. 1089-1095, 2010.
27. N. J. Saez, S. Senff, J. E. Jensen et al., "Spider-venom peptides as therapeutics, " Toxins, vol. 2, no. 12, pp. 2851-2871, 2010.
28. T.-J. Fu, U. R. Abbott, and C. Hatzos, "Digestibility of food allergens and nonallergenic proteins in simulated gastric fluid and simulated intestinal fluid-a comparative study, " Journal of Agricultural and Food Chemistry, vol. 50, no. 24, pp. 7154-7160, 2002.
29. M. Werle, T. Schmitz, H.-L. Huang, A. Wentzel, H. Kolmar, and A. Bernkop-Schnurch, "The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery, " Journal of Drug Targeting, vol. 14, no. 3, pp. 137-146, 2006.
30. H. Li, J. J. Bowling, M. Su et al., "Asteropsins B-D, spongederived knottins with potential utility as a novel scaffold for oral peptide drugs, " Biochimica et Biophysica Acta-General Subjects, vol. 1840, no. 3, pp. 977-984, 2014.
31. R. E. Middleton, V. A. Warren, R. L. Kraus et al., "Two tarantula peptides inhibit activation of multiple sodium channels, " Biochemistry, vol. 41, no. 50, pp. 14734-14747, 2002.
32. B. T. Priest, K. M. Blumenthal, J. J. Smith, V. A. Warren, and M. M. Smith, "ProTx-I and ProTx-II: gating modifiers of voltagegated sodium channels, " Toxicon, vol. 49, no. 2, pp. 194-201, 2007.
33. K. L. Ostrow, A. Mammoser, T. Suchyna et al., "cDNA sequence and in vitro folding of GsMTx4, a specific peptide inhibitor of mechanosensitive channels, " Toxicon, vol. 42, no. 3, pp. 263-274, 2003.
34. T. M. Suchyna, J. H. Johnson, K. Hamer et al., "Identification of a peptide toxin from Grammostola spatulata spider venom that blocks cation-selective stretch-activated channels, " Journal of General Physiology, vol. 115, no. 5, pp. 583-598, 2000.
35. J. H. Park, K. P. Carlin, G. Wu et al., "Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels, " Journal of Medicinal Chemistry, vol. 57, no. 15, pp. 6623-6631, 2014.
36. M. Werle, K. Kafedjiiski, H. Kolmar, and A. Bernkop-Schnurch, "Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration, " International Journal of Pharmaceutics, vol. 332, no. 1-2, pp. 72-79, 2007.
37. M. Werle, H. Kolmar, R. Albrecht, and A. Bernkop-Schnurch, "Characterisation of the barrier caused by luminally secreted gastro-intestinal proteolytic enzymes for two novel cystineknot microproteins, " Amino Acids, vol. 35, no. 1, pp. 195-200, 2008.
38. W. A. Schmalhofer, J. Calhoun, R. Burrows et al., "ProTx-II, a selective inhibitor of NaV1. 7 sodium channels, blocks action potential propagation in nociceptors, "Molecular Pharmacology, vol. 74, no. 5, pp. 1476-1484, 2008.
39. S. J. Moore, C. L. Leung, H. K. Norton, and J. R. Cochran, "Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging, " PLoS ONE, vol. 8, no. 4, Article ID e60498, 2013.
40. R. B. Shah, F. Ahsan, and M. A. Khan, "Oraldelivery ofproteins: progress and prognostication, " Critical Reviews in Therapeutic Drug Carrier Systems, vol. 19, no. 2, pp. 135-169, 2002.
41. J. F. Woodley, "Enzymatic barriers for GI peptide and protein delivery, " Critical Reviews inTherapeutic Drug Carrier Systems, vol. 11, no. 2-3, pp. 61-95, 1994.
42. D. Guggi, A. H. Krauland, and A. Bernkop-Schnurch, "Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin, " Journal of Controlled Release, vol. 92, no. 1-2, pp. 125-135, 2003.
43. R. H. Kimura, Z. Cheng, S. S. Gambhir, and J. R. Cochran, "Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects, " Cancer Research, vol. 69, no. 6, pp. 2435-2442, 2009.
44. A. P. Silverman, A. M. Levin, J. L. Lahti, and J. R. Cochran, "Engineered cystine-knot peptides that bind αvβ3 integrin with antibody-like affinities, " Journal of Molecular Biology, vol. 385, no. 4, pp. 1064-1075, 2009.
45. C. Souriau, L. Chiche, R. Irving, and P. Hudson, "New binding specificities derived from Min-23, a small cystine-stabilized peptidic scaffold, " Biochemistry, vol. 44, no. 19, pp. 7143-7155, 2005.
46. F. Stricher, C.-C. Huang, A. Descours et al., "Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein, " Journal of Molecular Biology, vol. 382, no. 2, pp. 510-524, 2008.
47. B. Glotzbach, M. Reinwarth, N. Weber et al., "Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1, " PLoS ONE, vol. 8, Article ID e76956, 2013.
48. T. Kubo, S. Ono, T. Kimura et al., "Randompeptide librarybased on spider neurotoxin, and utilization of the library in in vitro evolution derected to GPCR ligands, " Toxicon, vol. 60, p. 113, 2012.